In a post-hoc analysis of 89bio's ENLIVEN phase 2b trial of pegozafermin presented at The Liver Meeting, data suggested that the therapy reduced progression to cirrhosis for MASH patients
- Nov 16, 2024
- 1 min read
CEO Rohan Palekar describes this result that was presented at the meeting, as well as other biomarker findings. Plus, he highlights three phase 3 trials the company currently has ongoing, including one that will read out next year.
.png){kind=logo}